Aptamer Group Revenue Jumps 27% on Pharma Deals

Revenue Growth Driven by Pharmaceutical Contracts

Aptamer Group, a UK-based developer of synthetic binders, announced a 27% year-over-year increase in its first-half revenue. The growth was primarily fueled by new and repeat fee-for-service agreements with major pharmaceutical companies, including a significant contract in the radioligand therapy sector.

Financial Performance and Capital Position

The company reported a narrowed adjusted EBITDA loss of £1.0 million for the period, reflecting improved revenue and controlled operational costs. Gross profit stood at £460,000, while the reported EBIT was a loss of £1.24 million. To strengthen its financial position, Aptamer launched an Accelerated Book Build to raise a minimum of £3.75 million, which is expected to extend its cash runway through 2028.

Strategic Outlook and Licensing Agreements

Aptamer is actively working to convert its asset portfolio into a source of recurring royalty and licensing revenues. The company has already received initial payments from licensing deals with Twist Bioscience and Alphazyme, with further discussions in progress. Looking ahead, the firm is targeting the delivery of in vivo data for its radiopharmaceutical pipeline by the end of 2026 and plans to expand manufacturing capacity.

Summary

Aptamer Group's first-half results demonstrate strong commercial traction within the pharmaceutical industry. The combination of revenue growth, a narrowed loss, and strategic fundraising positions the company to advance its pipeline and transition towards a more sustainable, royalty-based business model.

FAQ

Q: What was the main driver of Aptamer Group's 27% revenue growth?
A: The revenue increase was driven by new and repeat fee-for-service contracts with pharmaceutical firms, particularly in areas like radioligand therapy.

Q: How is Aptamer Group planning to fund its future operations?
A: The company is raising at least £3.75 million through an Accelerated Book Build, which is projected to provide a cash runway through 2028.

Source: Investing.com